Video

Study finds differences for HCC in women


 

REPORTING FROM DDW 2019

SAN DIEGO – Hepatocellular carcinoma is the third leading cause of cancer-related death in the United States and its incidence is increasing worldwide. While it affects men much more frequently than women, approximately 4 to 1, the differences in risk factors between men and women have never been studied.

At the annual Digestive Disease Week, Meaghan Phipps, MD, of New York–Presbyterian Hospital, described in a video interview how she and her colleagues set up a retrospective study of these differences in 5,327 patients at five large academic centers around the country. She and her colleagues found that women tended to present later, and with less severe disease, which was more likely to be treated with resection than transplantation. Women had better overall survival. Women were significantly more likely to present without cirrhosis and with nonalcoholic fatty liver disease than were men. Dr. Phipps noted that they did not characterize the women in their study by menopausal status, and suggested that this would be an important thing to look at in a future prospective study because it has long been thought that estrogen confers some protection against hepatocellular carcinoma.

Recommended Reading

Pembro as good as chemo for gastric cancers with less toxicity
MDedge Hematology and Oncology
Maintenance olaparib extends PFS in pancreatic cancer with BRCA mutation
MDedge Hematology and Oncology
Adjuvant CAPOX: Three months may be as good as 6 in high-risk stage II colon cancer
MDedge Hematology and Oncology
Pembrolizumab missed statistical cutoffs in hepatocellular carcinoma study
MDedge Hematology and Oncology
Laparoscopic surgery survival outcomes on par with open approach in colorectal liver metastases
MDedge Hematology and Oncology
Jury still out on gemcitabine/nab-paclitaxel as treatment for pancreatic cancer
MDedge Hematology and Oncology
Pazopanib extended PFS in patients with carcinoid tumors
MDedge Hematology and Oncology
Second-line chemo sets benchmark in biliary tract cancers
MDedge Hematology and Oncology
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancer
MDedge Hematology and Oncology
Rivaroxaban tied to higher GI bleeding than other NOACs
MDedge Hematology and Oncology